cResponse™ Research and Evidence

The cResponse™ platform:

Ex vivo organotypic cultures for synergistic therapy prioritization identify patient-specific responses to combined MEK and Src inhibition in colorectal cancer


Clinical trial of cResponse, a functional assay for cancer precision medicine. Poster presentation American Association for Cancer Research (AACR), April, 2022.

Curesponse Related Research

Nature Communication

Ben-Hamo R., Berger AJ., Gavert N., et al. Predicting and affecting response to cancer therapy based on pathway-level biomarkers. Nat Commun. 2020 Jul 3;11(1):3296.

Cancer Bioology

Grinshpun A, Gavert N, Granit RZ., et al. Ev vivo organ culture as potential prioritization tool for breast cancer targeted therapy. Cancer Biol Ther. 2018 Aug 3;19(8):645-648.


Geller LT., Barzily-Rokni M., Danino T., et al. Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine. Science. 2017 Sep 15;357(6356):1156-1160.


Straussman R., Morikawa T., Kevin Shee K., et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature. 2012 Jul 26; 487(7408): 500–504.

Biomedicines logo
Comparing intraperitoneal and intravenous personalized ErbB2CAR-T for the treatment of epithelial ovarian cancer. Biomedicines. 2022 Sep 7;10(9):2216.